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Abstract
Background: Cardiopulmonary bypass (CPB) surgery initiates a systemic inflammatory response, which is associated
with postoperative morbidity and mortality. Hemoadsorption (HA) of cytokines may suppress inflammatory responses
and improve outcomes. We tested a new sorbent used for HA (CytoSorb™; CytoSorbents Europe GmbH, Berlin,
Germany) installed in the CPB circuit on changes of pro- and anti-inflammatory cytokines levels, inflammation markers,
and differences in patients’ perioperative course.
Methods: In this first pilot trial, 37 blinded patients were undergoing elective CPB surgery at the Medical University of
Vienna and were randomly assigned to HA (n = 19) or control group (n = 18). The primary outcome was differences of
cytokine levels (IL-1β, IL-6, IL-18, TNF-α, and IL-10) within the first five postoperative days. We also analyzed whether we
can observe any differences in ex vivo lipopolysaccharide (LPS)-induced TNF-α production, a reduction of high-mobility
box group 1 (HMGB1), or other inflammatory markers. Additionally, measurements for fluid components, blood
products, catecholamine treatment, bioelectrical impedance analysis (BIA), and 30-day mortality were analyzed.
Results: We did not find differences in our primary outcome immediately following the HA treatment, although we
observed differences for IL-10 24 hours after CPB (HA: median 0.3, interquartile range (IQR) 0–4.5; control: not traceable,
P = 0.0347) and 48 hours after CPB (median 0, IQR 0–1.2 versus not traceable, P = 0.0185). We did not find any
differences for IL-6 between both groups, and other cytokines were rarely expressed. We found differences in
pretreatment levels of HMGB1 (HA: median 0, IQR 0–28.1; control: median 48.6, IQR 12.7–597.3, P = 0.02083) but no
significant changes to post-treatment levels. No differences in inflammatory markers, fluid administration, blood
substitution, catecholamines, BIA, or 30-day mortality were found.
Conclusions: We did not find any reduction of the pro-inflammatory response in our patients and therefore no
changes in their perioperative course. However, IL-10 showed a longer-lasting anti-inflammatory effect. The clinical
impact of prolonged IL-10 needs further evaluation. We also observed strong inter-individual differences in cytokine
levels; therefore, patients with an exaggerated inflammatory response to CPB need to be identified. The
implementation of HA during CPB was feasible.
Trial registration: ClinicalTrials.gov: NCT01879176, registration date: June 7, 2013.
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Background
Cardiopulmonary bypass (CPB) surgery initiates a sys-
temic inflammatory response induced by extrinsic and in-
trinsic factors [1–3]. Monocytes and high-mobility group
box 1 protein (HMGB1), a chromatin protein, encoded by
the Hmgb1 gene in humans, are important players in sys-
temic inflammation and belong to the main producers of
pro- and anti-inflammatory cytokines [4, 5]. Once acti-
vated by the extracorporeal circuit, they might lead to a
dysregulation of inflammatory homeostasis and increased
levels of both, pro- and anti-inflammatory plasma media-
tors such as tumor necrosis factor-alpha (TNF-α),
interleukin-1β (IL-1β), IL-6, IL-10, and IL-18 [4, 6–9].
This strong inflammatory response induces post-surgical
monocyte immunosuppression which is indicated by an
impaired production of ex vivo lipopolysaccharide (LPS)-
induced TNF-α exaggeration [10].
All of these factors may lead to a prolonged postopera-
tive course, including a delayed weaning from mechanical
ventilation, recovery of organ functions, and discharge
from the intensive care unit (ICU). Thus, measures to
decrease the inflammatory process have the potential
to improve the perioperative course [11]. Hemoadsorption
(HA) using the CytoSorb™ adsorber (CytoSorbents Europe
GmbH, Berlin, Germany) is a recent technology that
has shown rapid elimination of many key cytokines
that cannot be filtered by using current blood purification
techniques [12].
The primary aim of this first single-center, blinded,
randomized, and controlled pilot study was to investi-
gate differences of pro- and anti-inflammatory cytokines
in patients undergoing cardiac surgery with CPB using
the CytoSorb™ adsorber compared with a control group
within the first 5 postoperative days (POD). Further-
more, we investigated whether we can observe any dif-
ferences in ex vivo LPS-induced TNF-α production, a
reduction of HMGB1, or other inflammatory markers.
Also, we investigated differences in fluid management or
the use of catecholamines and differences in edema for-
mation as determined by analysis of body composition
by bioelectrical impedance analysis (BIA). Additionally,




This study was approved by the ethics committee of the
Medical University of Vienna with reference number EK
Nr: 1095/2013. Furthermore, we reported the study to
the Austrian Federal Office for Safety in Health Care
(INS-621000-0505) and registered it at ClinicalTrials.gov
(NCT01879176) before recruitment started. Written in-
formed consent to participate and consent to publish
were obtained from each patient.
Study design and patients
This study was a randomized, blinded (in patients), con-
trolled, single-center trial in 46 adult patients undergo-
ing elective open heart surgery (coronary artery bypass
graft [CABG], valve surgery, combined procedure) with
an expected CPB duration of more than 120 minutes at
the Department of Cardiac Surgery, Medical University of
Vienna, Vienna, Austria. The study was conducted be-
tween Sept. 10, 2013, and May 6, 2015, at our department.
We excluded the following interventions or condi-
tions: declined informed consent, transplant surgery,
scheduled insertion of a cardiac assist device, thromben-
darterectomy of the pulmonary arteries, emergency and
urgent procedures, serum creatinine of more than 2 mg/
dl, C-reactive protein (CRP) of more than 2 mg/dl, bili-
rubin of more than 2 mg/dl, body mass index (BMI) of
less than 18 kg/m2, pregnancy, history of stroke, and pa-
tients receiving chemotherapy, anti-leukocyte drugs,
TNF-α blockers, immunosuppressive drugs (e.g., toci-
lizumab) or with any diagnosed disease state that has
produced leukopenia (e.g., acquired immune deficiency
syndrome). Patient selection is shown in Fig. 1.
Randomization
Eligible patients were enrolled the day before surgery by
one of the physicians involved in the study and ran-
domly assigned into one of two groups (HA or control).
Randomization was performed as block randomization
by the online Randomizer for Clinical Trials 1.7.0
(https://www.meduniwien.ac.at/randomizer). To create
homogenous and comparable groups, the randomization
was stratified by sex and procedures.
Outcomes
Primary outcome
Primary outcomes were differences in the evolution of
cytokines using the CytoSorb™ adsorber for HA during
cardiopulmonary bypass.
Secondary outcomes
Secondary outcomes were differences in LPS-induced
release of TNF-α; differences in the expression of
HMGB1; changes in serum CRP or procalcitonin (PCT)
concentrations; differences in the need of fluid compo-
nents (crystalloid and colloid solutions), blood products
(erythrocytes, fresh frozen plasma, and platelets), or cat-
echolamine treatment; and changes in BIA, length of
ICU stay, and 30-day mortality.
Number of patients
The fact that this is the first randomized controlled
study and no prior data to cytokine level alterations in
cardiac surgery patients using this HA device were avail-
able made us consider a mean difference of one standard
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deviation between groups as a clinically relevant effect.
Under this assumption, we calculated by using a t test a
total of 16 individuals per group that are required to
achieve 80 % power with a significance level of 5 %.
Therefore, we planned a total of 40 patients to allow an
adequately powered analysis with 20 % dropouts for
complicated intraoperative course. To avoid the risk of
low power, we increased the number of patients to 46
after the completion of the 36th patient because a total
of 7 patients dropped out at this time.
Data collection
Preoperative patient data (age, weight, height, sex, BIA,
European system for cardiac operative risk evaluation
[EuroSCORE], diagnosis, preoperative myocardial infarc-
tion within 24 hours [MCI], history of asthma bronchiale,
chronic obstructive pulmonary disease [COPD], insulin or
non-insulin-dependent diabetes mellitus [IDDM, NIDDM],
history of chronic kidney disease [CKD], dialysis, left
ventricular ejection fraction [LVEF], stable and unstable
angina pectoris, cardial decompensation, peripheral arter-
ial obstructive disease [PAOD], and arterial hypertension),
surgery-related factors (kind of operation, duration of
anaesthesia and surgery duration of CPB and aortic
cross-clamp [AoCC], unplanned insertion of assist de-
vices, amount of fluids [cristalloids or colloids], need of
catecholamines [noradrenalin, dobutamin, levosimendan,
vasopressin, or milrinon], and need of blood products
[erythrocytes, fresh frozen plasma, or thrombocytes] or
coagulation factors [fibrinogen, prothrombin complex
concentrate, desmopressin, or recombinant factor VIIa]),
intraoperative diuresis and postoperative data (use of
catecholamines, BIA, length of stay on intensive care unit
[LOS-ICU], length of mechanical ventilation, or need of
extracorporeal membrane oxygenation [ECMO]) were
collected by a case report form.
Procedure
Anaesthesia was induced and CPB circuit was primed
(1000 ml crystalloid and 500 ml colloid solution together
with 5000 IE heparin, and 100 ml mannitol 20 %) in
accordance with institutional standards. CPB was per-
formed by using non-pulsatile flow at 2.5 l · min−1 · m−2, a
non-heparin-coated circuit, and a membrane oxygenator
(Quadrox™, Maquet, Hirrlingen, Germany, or Capiox, Ter-
umo, Eschborn, Germany). All study cases were per-
formed by experienced cardiac anaesthesia fellows
supervised by senior cardiac anaesthesiologists, both
trained in transesophageal echocardiography (TOE),
which was used to monitor myocardial performance and
the impact of fluid loading and inotropic support on left
and right ventricular function. Blood transfusion was per-
formed in accordance with Society of Thoracic Surgeons/
Society of Cardiovascular Anesthesiologists (STS-SCA)
transfusion guidelines [13, 14], and administration of co-
agulation factors was based predominantly on rotational
thromboelastometry (ROTEM) variables and the coagula-
tion profile of each patient.
In the intervention group, we installed the 300 ml
CytoSorb™ adsorber on the CPB machine. The active
component of the CytoSorb™ device consists of adsorb-
ent polymer beads composed of porous polymerized
Fig. 1 The selection process for patients included in the study
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divinylbenzene. These beads have pores that can adsorb
hydrophobic molecules in a size range of approximately
10 to 55 kD, which is sufficient to remove almost all
known cytokines. The polymer beads are encased in a
polycarbonate canister commonly used in commercially
available dialyzers. Blood was pumped actively through
the CytoSorb™ cartridge by using a side arm coming
from the venous outflow tube and given back to the ven-
ous reservoir prior to the oxygenator. The flow through
the cartridge was controlled by a roller pump with
200 ml/min to standardize flow conditions in all treated
patients. The addition of 20 ml crystalloid solution was
necessary to fill the additional line in the treatment
group. The control group was treated similarly, but no
adsorber was installed.
Blood sampling
Blood samples were drawn in pyrogen-free vials, and
plasma was separated by centrifugation and frozen
(−80 °C). Blood samples for cytokines (IL-1β, IL-6, IL-
18, TNF-α, and IL-10) were determined at the following
time points: A, before induction of anesthesia; B, before
CPB; C, at the end of CPB; D, 2 hours after CPB; E,
24 hours after CPB; F, 48 hours after CPB; and G,
120 hours after CPB. The ex vivo LPS-induced TNF-α
production was measured at the time points A–C, F, and
G; and HMGB1 at time points B, D, and E. For the
quantification of IL-1β, IL-6, TNF-α, and IL-10, we used
the BD™ Cytometric Bead Array (CBA) Human Inflamma-
tory Cytokines (BD Biosciences Europe, Erembodegem,
Belgium) Kit; for quantification of IL-18, Human IL-18 In-
stant, ELISA (eBioscience, Inc., San Diego, CA, USA), and
for quantification of HMGB1 the high-mobility group box
1 (HMGB1), ELISA Kit (MyBioSource, Inc., San Diego,
CA, USA). For the measurement of ex vivo LPS-induced
TNF-α, lipopolysaccharide from Escherichia coli was
purchased (Sigma-Aldrich GmbH, Vienna, Austria) and
prepared. For the analysis of LPS-induced TNF-α release,
Human TNF-α Instant, ELISA (eBioscience, Inc.) was per-
formed on each sample. All analysis were conducted in ac-
cordance with the protocol of the manufacturer.
Blood samples for CRP, procalcitonin, albumine, fi-
brinogen, hemoglobin, thrombocytes, and leukocytes
were determined at the following time points: a baseline
value within 24 hours preoperatively (BL), 1st postopera-
tive morning (1.POD), 2nd postoperative morning
(2.POD), and 5th postoperative morning (5.POD).
Bioelectrical impedance analysis
We performed BIA by using 800 μA at 50 kHz with a
single-frequency bioimpedance analyzer (Model BIA 101;
Akern-RJL, Pontassieve, Italy). The skin was cleaned, and
adhesive pregelled electrodes (Bianostic AT; Data-Input
GmbH, Wedemark, Germany) were placed on the hand
(source on the third metacarpophalangeal joint and
the detector on wrist, between the distal prominences
of the radius and ulna) and the foot (source on the
third metatarsophalangeal joint and the detector on
the ankle, between the medial and lateral malleoli) of the
right side while patients where in a recumbent position
with the limbs abducted from the body. Measurements
were performed within 24 hours preoperatively, 1.POD,
2.POD, and 5.POD. The measured BIA variables were re-
sistance (R), reactance (Xc), the phase angle (arctanXc/R),
and total body water (TBW). TBW was calculated by
the following formulas according to the BIA analyzer
we used [15, 16]:
Female : TBW ¼ 0:382  Ht2=Rð Þ þ 0:105  weightþ 8:315
Male : TBW ¼ 0:396  Ht2=Rð Þ þ 0:143  weightþ 8:399:
Statistical analysis
Demographic and clinical baseline data were summa-
rized by mean and standard deviation or mean and
range, expressed through minimum and maximum, for
metric variables or absolute frequencies for categorical
variables. Differences between groups were analyzed by
using the Student’s t test for continuous variables and
Fisher’s exact test for categorical variables.
The distributions of the cytokine levels were highly
skewed; therefore, between-group differences of these
variables were assessed by using the non-parametric
Wilcoxon rank-sum test. The distributions were described
by median and interquartile range (IQR) expressed
through the first quartile and the third quartile.
The distributions of laboratory values were largely
symmetric without severe outliers. These variables were
described by mean and standard deviation, and the effect
of HA was assessed by using analysis of covariance
(ANCOVA) models. In these models, the outcome is ex-
plained by the treatment group (HA versus control), the
stratification variables (procedure and sex), and the ob-
served preoperative baseline value (except when analyz-
ing the baseline differences). To describe the correlation
between cytokine levels and duration of procedure, we
calculated Spearman’s rank correlation coefficients at the
end of treatment time (time point C).
The analysis of IL-10 suggests that the decrease after
HA may follow an exponential function. To investigate
this, we fitted the following model for time-dependent
decay of IL-10 for each group by using the non-linear
least squares method: mean IL-10 = A*exp(λ*time).
Also, to obtain a robust global test, we used a re-
randomization test with 10,000 repeats. The patients
were repeatedly randomly assigned anew with the
same block randomization procedure as originally ap-
plied. In each repeat, a chi-squared-type statistic and
a P value were calculated as the proportion of
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resampled statistics being equal to or larger than the
observed statistic.
Results
In total, 46 patients were included in the study and ran-
domly assigned into one of two groups (HA or control).
Nine patients (5 HA and 4 control) dropped out of the
study after randomization: In six patients, the procedure
was scheduled to another day or later in the day, when
the study team was no longer available. One patient
(HA) evolved a hemodynamical instability after skin in-
cision leading to cardiopulmonary resuscitation and an
acute onset of the CPB, so no adsorber could be in-
stalled, and in two patients (1 HA and 1 control) we lost
the follow-up of our main outcome measurements, so
we excluded them too. Finally, we analyzed 37 patients;
19 patients were randomly assigned to the HA group
and 18 patients to the control group. For the analysis of
our primary outcome, we excluded the patients with un-
expected post-treatment ECMO therapy (n = 2) because
of differences in cytokine exaggeration (Fig. 1). Our
patients had a mean age of 66 ± 12 years, the mean
EuroSCORE was 5.4, 30 % of them were female, and
the mean temperature during CPB was 33 ± 2 °C. All
patients survived the 30-day period, except one pa-
tient (HA) who died on the 22nd postoperative day
because of multiple surgical complications. All other
pre-, intra-, and post-operative patient characteristics
showed no difference between both groups. Detailed
results are shown in Table 1.
Primary outcome
We measured high amounts of IL-6 in both groups in-
creasing after CPB and with a peak value 2 hours after
CPB (HA: median 120.8, IQR 49.0–160.8 versus control:
median 118.7, IQR 68.4–255.9, pg/ml, P = 0.6781). One
patient (control) showed an increase of IL-6 after skin
incision (2.1 pg/ml); in all other patients, the activation
started during CPB. No significant difference was found
between the treatment and control group for all time
points. The correlations for IL-6 and the end of treat-
ment duration were 0.34 for the HA group and 0.46 for
the control group.
For IL-10, we observed an increase in one patient
(HA) after inducing anesthesia (11.3 pg/ml). In four pa-
tients (2 HA and 2 control), the activation of IL-10
started before CPB; one of those also had an increase of
IL-6. We did not find any similarities in those patients
with pre-CPB increased levels of cytokines. IL-10
reached a peak value at the end of CPB (HA: median
13.1, IQR 3.3–18.7 versus control: median 18.5, IQR
5.7–68.0 pg/ml, P = 0.1562). The decrease of IL-10
seems to be earlier in the control group showing signifi-
cant differences 24 hours after CPB (HA: median 0.3,
IQR 0–4.5 pg/ml versus control: median 0, P = 0.0347)
and 48 hours after CPB (HA: median 0, IQR 0–1.2 pg/
ml versus control: not traceable, P = 0.0185). The corre-
lations for IL-10 and the end of treatment time were
0.02 for the HA group and 0.32 for the control group.
The exponential decay model matched rather well the
observed mean values and showed different characteris-
tics for the two groups (P = 0.0188). For detailed results
of the analysis of the cytokine evolution, see Table 2 and
Figs. 2 and 3.
We detected traceable values in only two patients for
TNF-α and IL-18 and in one patient for IL-1β over the
perioperative period. Therefore, we did not perform any
statistical analysis on TNF-α, IL-18, and IL-1β.
Owing to technical problems with thawing of our fro-
zen blood samples, we additionally lost one patient in
the HA group and two patients in the control group. So
we were able to analyze our primary outcome in only 16
patients in the HA group and 16 patients in the control
group (Fig. 1).
Secondary outcome parameters
Ex vivo LPS-induced TNF-α exaggeration could be stim-
ulated at all determined time points. We observed a sig-
nificant difference between both groups preoperatively
(HA: median 2216, IQR 1742–2659 versus control:
median 3364, IQR 2579–4893 pg/ml, P = 0.004) and a
reduction of LPS-induced TNF-α after CPB but no signifi-
cant difference between both groups. On the 2.POD, LPS-
induced TNF-α reached again preoperative values but
showed a significant lower amount in the HA group (HA:
median 788, IQR 679–1272 versus control: median 3959,
IQR 2088–4777 pg/ml, P = 0.0115) as well as on 5.POD
(HA: median 1737, IQR 843–2535 versus control: median
3358, IQR 3017–3672 pg/ml, P = 0.0205). Unfortunately,
we were able to analyze only 18 (9 HA and 9 control) pa-
tients on 2.POD and 17 (9 HA and 8 control) patients on
5.POD (Table 2).
HMGB1 showed a significantly different expression
at baseline before treatment (HA: median 0, IQR 0–28.1
versus control: median 48.6, IQR 12.7–597.3 pg/ml,
P = 0.0208) but no differences in the period after
CPB, although post-treatment maximum levels in the
control group were nearly double that of the HA
group (HA: 705 versus control: 1594 pg/ml). The
post hoc analysis was possible in 29 patients (15 HA
and 14 control). We did not observe any differences
in other inflammation markers like CRP or PCT or
differences in leukocytes, thrombocytes, hemoglobin,
albumin, or fibrinogen levels. The analysis of differences
before and after intervention within the groups resulted in
significant decreases in hemoglobin, albumin, and throm-
bocytes, according to hemodilution, as well as significant
increases in CRP and leukocytes, according to usual
Bernardi et al. Critical Care  (2016) 20:96 Page 5 of 13
Table 1 Patient and surgical characteristics
HA (n = 19) Control (n = 18) OR (95 % CI) P value
Preoperative characteristics
Age, years 64 (30–81) 69 (51–81) 0.1737
Male 12 14 0.50 (0.09, 2.56) 0.4756
Female 7 4
BMI, kg/m2 27 (18–35) 27 (20–39) 0.6593
EuroSCORE 4.0 ± 3.6 6.0 ± 4.6 0.154
Resistance 411.7 ± 210.2 442.7 ± 101.6 0.6948
Phase angle 5.1 ± 1.5 4.9 ± 0.7 0.7078
TBW 56.3 ± 14.1 46.6 ± 11.3 0.1205
MCI 0 0 1
Asthma 0 0 1
COPD 3 3 0.94 (0.11–8.15) 1
NIDDM 6 4 1.60 (0.30–9.56) 0.714
IDDM 0 2 0 (0, 4.99) 0.2297
CKD 0 0 1
Cardiac decompensation 2 1 1.96 (0.09–124.72) 1
PAOD 3 1 3.10 (0.22–176.81) 0.6039
Art. hypertension 10 10 0.89 (0.20–3.90) 1
Dialysis 0 0 1
Angina pectoris (absence of) 16 13 0.5392
Angina pectoris (stable) 3 4
Angina pectoris (instable) 0 1
LVEF >50 % 12 13 0.4756
LVEF 30–50 % 7 4
LVEF <30 % 0 1
Intraoperative characteristics
Valve procedure, M/F 7/4 7/4 0.4819
CABG, M/F 2/1 5/0
Combined procedure, M/F 3/2 2/0
Anesthesia time, min 474 (290–673) 427 (277–570) 0.1683
Surgery time, min 369 (219–630) 327 (225–493) 0.2152
CPB time, min 191 (112–288) 170 (83–274) 0.2064
AoCC time, min 138 (57–242) 117 (36–179) 0.1423
Fibrinogen, g 1.7 (0–5) 0.8 (0–4) 0.077
Thrombocytes, units 0.15 (0–1) 0.2 (0–1) 0.6304
PCC, IE 605 (0–2000) 389 (0–3000) 0.415
FFP, units 0.5 (0–9) 0 0.3306
Erythrocytes, units 1.4 (0–7) 0.7 (0–3) 0.2021
Cristalloids, ml 5239 ± 1569 4311 ± 1230 0.0526
Colloids, ml 571 ± 327 514 ± 130 0.4873
Diuresis 826 ± 352 978 ± 589 0.3516
Postoperative characteristics
LOS-ICU, days 2.3 ± 2.0 2.4 ± 1.9 0.8721
Mechanical ventilation, days 0.7 ± 1.6 0.2 ± 0.4 0.19
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postoperative inflammation, within both groups. We did
not find differences in the change of PCT, HMGB1, or
fibrinogen levels within both groups. Detailed information
is shown in Tables 3 and 4.
We performed a BIA in 19 patients (9 HA and 10
control). However no differences in baseline values in
resistance, phase angle, or TBW were observed between
both groups (Table 5).
We also analyzed the need of catecholamines in both
groups within the first 24 hours, but we did not analyze
differences on day 2 or 5, because only 20 patients
(9 HA and 11 control) remained in the ICU after 24 hours.
We did not find any differences in the need of noradrena-
lin, dobutamin, or levosimendan, although it is worth
mentioning that only a total of eight patients received
dobutamin in the control group and 11 patients in the
HA group, as well as only eight (5 HA and 3 control) pa-
tients were treated with levosimendan (Table 6).
Discussion
Cardiac surgery is associated with an unpredictable
activation of the immune system with an increase of pro-
inflammatory cytokines as well as a decrease of anti-
inflammatory cytokines, which is caused by blood contact
with artificial surfaces and therefore is linked to adverse
outcomes [17, 18]. In this (to our knowledge) first con-
trolled study in patients undergoing on-pump cardiac sur-
gery treated with the CytoSorb™ adsorber, no significant
differences of pro-inflammatory cytokine levels were
found. Even though a reduction of absolute levels within
the first 24 hours after CPB is noticeable, no significant
changes were observed. Given that we did not observe
any adverse device-related side effects or differences in
reduction of blood cells or albumin, our study shows
that using the CytoSorb™ adsorber cartridge in a CPB
circuit is technically feasible.
The indication for the CytoSorb™ adsorber is to reduce
cytokine concentrations in various clinical situations
with elevated cytokine levels and has been tested previ-
ously and demonstrated significant cytokine adsorption
[19–21], an effect we could not reproduce in our patients.
There may be numerous reasons for that outcome: First,
we had a mean treatment time of 191 ± 56 minutes, which
may be too short to allow a significant reduction of
cytokine levels, although we did not find any correlation
between cytokine peaks and treatment time. In all previ-
ously conducted studies [19–21] and case reports [12, 22,
23], the treatment time was at least 4 hours up to 4 days.
In a CPB-porcine model with 5 hours of treatment time,
also no effect in IL-6 or TNF-α has been found [24]. Sec-
ondly, we effectively observed a CPB-triggered immunoac-
tivation and an increase in cytokines and inflammation
markers after CPB and therefore after HA treatment. So it
might be owing to a concentration-dependent adsorption
of CytoSorb™ that we did not observe any HA of cyto-
kines. Third, we may have expected a too optimistic effect
and therefore we may have planned a too small sample
size, a fact which is also shown by the observed strong
inter-individual differences in the amounts of cytokine
levels. But at the time of planning this pilot study, no clin-
ically relevant data concerning our primary outcome were
available. And, fourth, we included only the least sick co-
hort of patients undergoing cardiac surgery. Although we
did not restrict the EuroSCORE levels of our included pa-
tients, our exclusion criteria resulted in a moderate pre-
operative risk for postoperative outcomes. In a recently
published cohort analysis [25] representing more than
9,000 cardiac surgical patients operated at our center, we
found similar demographics, so that the population we in-
vestigated represents in our opinion a cross-section of
elective moderate-risk patients operated at our center.
We rarely observed the production of TNF-α in our
patients and this goes hand in hand with the contentious
role of TNF-α within CPB; although some studies have
shown an increase, others have not [26]. Also, IL-1β has
been found to be detectable in only a small proportion
of patients with systemic inflammatory response syn-
drome and sepsis [27].
IL-10 is thought to downregulate cytokine production
[27], and high concentrations have been observed in our
patients. Our results follow a similar time course to the
pro-inflammatory cytokines with an early peak and
subsequently falling concentrations. Interestingly, we
observed a slower decrease of postoperative IL-10
levels in the HA group and therefore a longer effect
up to 48 hours postoperatively. Recently, higher IL-10
levels following cardiac surgery have been associated
with a decreased risk of mortality [28]. Although we
Table 1 Patient and surgical characteristics (Continued)
Balance 1POD 9374 ± 4785 7303 ± 2664 0.1124
vaECMO, n 2 0 0.4865
30-day mortality 1 0 1
Values are presented as number (n), percentage (%), mean (range), mean ± standard deviation (SD), or odds ratio (95 % confidence interval). The listed P values of
statistical tests were calculated by using t test for continuous and the Fisher’s exact test for categorical variables. Abbreviations: AP, angina pectoris; aHTN, arterial
hypertension; AoCC, aortic cross-clamp; BMI, body mass index; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; COPD, chronic obstructive
pulmonary disease; CPB, cardiopulmonary bypass; HA, hemoadsorption; IDDM, insulin-dependent diabetes mellitus; LOS-ICU, length of stay in intensive care unit;
LVEF, left ventricular ejection fraction; MCI, myocardial infarction; NIDDM, non-insulin-dependent diabetes mellitus; OR, odds ratio; PAOD, peripheral artery occlusive
disease; PCC, prothrombin complex concentrate; TBW, total body water; vaECMO, veno-arterial extra corporal membrane oxygenation
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Table 2 Comparison of cytokine levels
Treatment Preoperative Before CPB After CPB 2 hours after CPB 24 hours after CPB 48 hours after CPB 5.POD
IL-6, pg/ml HA Not traceable Not traceable 62.9 (10.8, 98.7) 120.8 (49.0, 160.8) 111.6 (53.7, 253.5) 89.0 (61.4, 160.5) 0.4 (0, 8.3)
Control Not traceable 0 63.6 (41.2, 154.9) 118.7 (68.4, 255.9) 120.9 (68.0, 198.5) 67.7 (43.7, 134.5) 8.2 (0.8, 19.4)
P value 0.3485 0.3267 0.6781 0.9837 0.3809 0.0999
IL-10, pg/ml HA 0 0 13.1 (3.3, 18.7) 5.9 (0.5, 12.9) 0.3 (0, 4.5) 0 (0, 1.2) 0
Control Not traceable 0 18.5 (5.7, 68.0) 2.3 (0, 11.6) 0 Not traceable Not traceable
P value 0.3485 1.0 0.1562 0.6743 0.0347 0.0185 0.3485
TNFα-LPS, pg/ml HA 2216 (1742, 2659) 2534 (914, 3023) 40 (1, 82) Non fec. Non fec. 788 (679, 1272) 1737 (843, 2535)
Control 3364 (2579, 4893) 3403 (1679, 4394) 77 (34, 316) Non fec. Non fec. 3959 (2088, 4777) 3358 (3017, 3672)
P value 0.004 0.1378 0.2049 0.0115 0.0205
HMGB1, pg/ml HA Non fec. 0 (0, 28.1) Non fec. 5.7 (0, 34.2) 0 (0, 72.5) Non fec. Non fec.
Control Non fec. 48.6 (12.7, 597.3) Non fec. 41.5 (4.5, 266.9) 26.2 (0, 281,2) Non fec. Non fec.
P value 0.0208 0.1327 0.3724
Values are presented as median (first quartile, third quartile). The listed P values were calculated by using Wilcoxon rank-sum tests. Abbreviations: CPB, cardiopulmonary bypass; HA, hemoadsorption; HMBG1,
high-mobility group box 1; IL, interleukin; fec., fecit; POD, postoperative day; TNF-α, tumor necrosis factor-alpha; TNFα-LPS, lipopolysaccharide-induced TNF-α
Bernardiet
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did not find a reduction in mortality, this arguable
immuno-protective effect needs to be investigated
further.
We also found significant time-dependent changes in
ex vivo LPS-induced TNF-α release. Surprisingly, we had
observed a lower stimulation rate in the HA group
already before treatment. That could be based on an ef-
fect modification of comorbidities like diabetes mellitus
(DM). There is good evidence that patients with DM are
associated with an immunosuppressive condition and
have poorer humoral response, including decreased
cytokine production, and therefore have an increased
susceptibility to infections [29–31]. Although there were
no differences between both groups, the lowest levels of
LPS-induced TNF-α release were found in HA-treated
patients with DM. Additionally, it may be an effect of an
associated, preoperative drug therapy such as metformin,
aspirin, or statins, which we did not record. HMGB1 is
associated with the inflammatory response after ischemia/
reperfusion injury after cardiopulmonary bypass, and
it has been shown that a reduction decreases the markers
indicating cardiac damage. Also, elevated levels of HMGB1
have been correlated with the disease severity of heart
failure [32–35]. However, we observed preoperative
Fig. 2 Comparison of median cytokine levels in picograms per milliliter. Red lines indicate the patients in the CytoSorb™ treatment group. Black
lines indicate the patients in the control group. Error bars correspond to interquartile ranges (first quartile, third quartile). Asterisks mark
differences between both groups at a significance P < 0.05
Fig. 3 Exponential decay model for mean interleukin-10 (IL-10). Black
circles indicate IL-10 values for the control group, and red squares
indicate IL-10 values for the CytoSorb™ group
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differences in HMGB1; therefore, it is not possible to
interpret the results if there is a post-treatment difference.
According to our LPS-induced TNF-α results, we cannot
rule out that there is a hidden phenotypic difference
between groups despite randomization that may be
associated with higher levels of HMGB1 before CPB. But
we think the effects of HMGB1 and HA on patients’ post-
operative course should be investigated further.
Last, we observed neither any differences in our pa-
tients’ body composition nor any need of catecholamines
or postoperative fluid balances. Therefore, we cannot
conclude that there is less edema formation in the HA
group. Unfortunately, we did not record systemic vascu-
lar resistance after CPB to assess that the HA group was
more vasodilated.
A limitation of a study such as ours may be effect
modifications owing to omitted or unobserved con-
founding risk indicators, although we included the most
relevant risk indicators to rule out any systematic effect.
However, we did not monitor the use of non-steroidal
anti-inflammatory drugs preoperatively (e.g., aspirin),
statins, or metformin, which may have anti-inflammatory
effects [36, 37]. Another limitation of our study can be
that our study design was not double-blinded, only
blinded in patients. Although blinding in studies involving
operative management and medical devices is rarely
feasible, we do not think that would have affected the
outcome. Additionally, owing to technical problems, we
were not able to perform BIA in every patient, and we
have to report that our BIA monitor is validated in
healthy subjects up to only 66 years [16]. Last, a limita-
tion of the study is that we did not observe the cytokine
levels before and after the HA cartridge and therefore
we cannot be sure what proportion of blood has been
treated. We can only estimate that despite the small
amount of 3 to 4 % total blood volume purified each
Table 3 Comparison of laboratory values
Treatment Time point
preoperative P value 1.POD P value 2.POD P value 5.POD P value
CRP, mg/dl HA 0.28 ± 0.2 6.29 ± 2.9 16.94 ± 5.3 10.09 ± 6.4
Control 0.19 ± 0.2 0.0966 7.01 ± 3.6 0.8779 15.38 ± 5.9 0.7084 6.36 ± 2.9 0.1438
Leukocytes, G/l HA 7.4 ± 2.5 11.7 ± 3.7 11.8 ± 4.2 10.1 ± 3.3
Control 6.7 ± 1.9 0.2905 12.6 ± 2.9 0.2621 12.7 ± 2.6 0.0935 8.9 ± 2.5 0.8714
PCT, ng/ml HA 0.12 ± 0.34 1.21 ± 2.53 1.69 ± 5.18 0.54 ± 1.10
Control 0.05 ± 0.03 0.5120 4.91 ± 16.20 0.3120 4.46 ± 15.66 0.4018 1.21 ± 3.57 0.3486
Hemoglobin, g/dl HA 13.6 ± 1.5 10.9 ± 1.2 10.1 ± 1.2 9.9 ± 1.4
Control 13.5 ± 1.4 0.3473 10.9 ± 1.1 0.8562 10.0 ± 0.8 0.9085 9.5 ± 1.1 0.4339
Albumin, g/l HA 41.9 ± 9.7 31.3 ± 15.6 29.0 ± 3.1 30.7 ± 3.5
Control 41.1 ± 3.3 0.8469 28.5 ± 3.2 0.5794 28.5 ± 4.7 0.7626 28.8 ± 3.6 0.5618
Fibrinogen, mg/dl HA 354.5 ± 51.3 319.7 ± 72.5 500.5 ± 125.8 605.7 ± 170.4
Control 332.2 ± 72.2 0.2491 325.4 ± 61.0 0.8966 496.8 ± 84.2 0.7786 553.6 ± 105.0 0.1542
Thrombocytes, G/l HA 229.4 ± 50.9 110.5 ± 45.7 101.2 ± 47.6 184.1 ± 102.5
Control 206.8 ± 97.4 0.2275 116.9 ± 46.9 0.3343 102.0 ± 46.6 0.9807 178.8 ± 99.5 0.9652
Values are presented as mean ± standard deviation. The listed P values of statistical tests were calculated by using analysis of covariance. Abbreviations: CRP, C-
reactive protein; HA, hemoadsorption; PCT, procalcitonin; POD, postoperative day
Table 4 Differences between preoperative and postoperative
values
Treatment Mean difference 95 % CI P value
CRP, mg/dl HA 6.0 −7.4, −4.6 <0.0001
Control 6.8 −8.6, 5.0 0.0002
Leukocytes, G/l HA 4.24 −5.82, −2.66 0.0115
Control 5.86 −7.47, −4.25 <0.0001
PCT, ng/ml HA 1.08 −2.24, 0.07 0.0649
Control 5.07 −13.64, 3.49 0.2271
Hemoglobin, g/dl HA −2.7 2.0, 3.3 <0.0001
Control −2.7 2.0, 3.4 <0.0001
Albumin, g/l HA −10.5 2.1, 19.0 0.0175
Control −12.6 11.2, 14.0 <0.0001
Fibrinogen, mg/dl HA −34.8 −1.7, 71.3 0.0607
Control −6.8 −22.6, 36.2 0.6332
Thrombocytes, G/l HA −119.0 99.2, 138.7 0.0006
Control −89.8 60.0, 119.7 <0.0001
HMGB 1, pg/ml HA 9.5 −38.3, 57.3 0.6764
Control 64.2 −70.9, 199.2 0.3235
Values are presented as mean difference and 95 % confidence interval (CI).
The listed P values of statistical tests were calculated by using paired t tests.
Abbreviations: CRP, C-reactive protein; HA, hemoadsorption; HMGB1, high-mobility
box group; PCT, procalcitonin
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minute, more than 99 % of the blood volume has passed
through the HA device after our mean treatment time of
191 minutes.
Conclusions
We claim that the use of the CytoSorb™ adsorber cart-
ridge in a CPB circuit is technically feasible. We ob-
served a longer-lasting anti-inflammatory effect of IL-10
in the HA group, which needs to be investigated further.
We did not observe significantly relevant changes in the
evolution of pro-inflammatory cytokines in patients
treated with the CytoSorb™ adsorber device during CPB.
However, we did not find any effects on our patients’ clin-
ical outcomes, although future studies should endeavour
to increase the sample size. By reason of several involved
pathways in the complex pathogenesis of the inflamma-
tory reaction to CPB, the inhibition of a single pathway
may not achieve sufficient inhibition of the entire
pro-inflammatory cascade to significantly improve clinical
outcomes [38]. We found an inhomogeneous inflamma-
tory response expressed by high inter-individual differ-
ences in cytokine levels between our patients. A greater
homogeneity may be achieved by identifying those pa-
tients or procedures, which are triggering an exaggerated
inflammatory response to CPB like patients with endocar-
ditis, procedures on the aortic arch needing hypothermic
cardiac arrest or transplant surgery. This hypothesis re-
quires further investigations.
Table 5 Comparison of bioelectrical impedance analysis
Treatment Time point
preoperative P value 1.POD P value 2.POD P value 5.POD P value
Resistance, Ω HA 411.7 ± 210.2 265.2 ± 38.8 250.9 ± 44.0 279.6 ± 55.0
Control 442.7 ± 101.5 0.6090 276.9 ± 88.3 0.9240 279.0 ± 86.7 0.5111 362.0 ± 232.8 0.3355
Phase angle, ° HA 5.1 ± 1.5 3.3 ± 1.3 2.2 ± 0.9 2.9 ± 1.1
Control 4.9 ± 0.7 0.4731 3.5 ± 1.3 0.6025 2.8 ± 1.1 0.3138 2.7 ± 1.2 0.8895
TBW, % HA 56.3 ± 14.1 69.3 ± 12.3 72.2 ± 12.5 66.9 ± 10.7
Control 46.6 ± 11.3 0.0966 65.0 ± 18.6 0.7449 63.9 ± 17.0 0.5622 56.8 ± 16.7 0.6776
Values are presented as mean ± standard deviation. The listed P values of statistical tests were calculated by using analysis of covariance. Abbreviations: HA,
hemoadsorption; POD, postoperative day; TBW, total body water
Table 6 Catecholamine treatment
Treatment Time point
before CPB P value After CPB P value 2 hours after CPB P value 1.POD P value
Noradrenalin, μg kg-1 min-1 Control Mean ± SD 0.03 ± 0.04 0.13 ± 0.11 0.08 ± 0.08 0.06 ± 0.10
Max 0.12 0.36 0.30 0.36
N 13 18 16 8
HA Mean ± SD 0.04 ± 0.05 0.13 ± 0.15 0.14 ± 0.20 0.07 ± 0.14
Max 0.18 0.62 0.74 0.6
N 14 0.3138 18 0.8503 14 0.3075 7 0.8771
Dobutamin, μg kg-1 min-1 Control Mean ± SD 0.15 ± 0.50 1.78 ± 2.38 1.50 ± 2.05 1.18 ± 1.64
Max 1.72 6.94 5.55 5.00
N 3 8 8 8
HA Mean ± SD 0.05 ± 0.23 2.30 ± 2.42 1.28 ± 1.51 1.32 ± 1.58
Max 1.00 8.00 4.1 5.34
N 1 0.4163 11 0.5136 10 0.7134 10 0.7871
Levosimendan, μg kg-1 min-1 Control Mean ± SD 0 0.03 ± 0.07 0.03 ± 0.07 0.01 ± 0.03
Max 0 0.2 0.2 0.1
N 0 3 3 2
HA Mean ± SD 0.02 ± 0.05 0.07 ± 0.18 0.04 ± 0.08 0.01 ± 0.03
Max 0.20 0.74 0.2 0.12
N 2 0.1868 5 0.3325 5 0.5228 1 0.6963
Values are presented as number (n), maximum value (max), or mean ± standard deviation (SD). The listed P values were calculated by using t tests. Abbreviations:
CPB, cardiopulmonary bypass; HA, hemoadsorption; POD, postoperative day
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Key messages
 Using the CytoSorb™ adsorber during
cardiopulmonary bypass did not change patients’
perioperative course.
 Activation of cytokines due to cardiopulmonary
bypass is inhomogeneous and shows high
inter-individual differences between our patients.
Patients with an exaggerated inflammatory
response to cardiac surgery need to be identified.
 A longer-lasting anti-inflammatory effect of IL-10
was observed in patients who were treated with
hemadsorption.
 The use and installation of the CytoSorb™ adsorber
on CPB were technically feasible, and no adverse
device-related side effects occurred.
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